Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats

Journal of Dairy Science

Volumn 90, Issue 9, 2007, Pages 4219-4225

  Marin P ^a   Escudero, E ^a   Fernandez Varon E ^a   Carceles C M ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Lactating goat; Milk; Orbifloxacin; Pharmacokinetics

Indexed keywords

CAPRA HIRCUS;

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DRUG DERIVATIVE; ORBIFLOXACIN;

ANIMAL; ARTICLE; CHEMISTRY; CROSSOVER PROCEDURE; FEMALE; GOAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; LACTATION; METABOLISM; MILK; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CROSS-OVER STUDIES; FEMALE; GOATS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KINETICS; LACTATION; MILK;

EID: 34848869764     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2007-0071     Document Type: Article

References (36)

1. Abd El-Aty, A. M., and A. Goudah. 2002. Some pharmacokinetic parameters of Pefloxacin in lactating goats. Vet. Res. Commun. 26:553-561.
2. Aliabadi, F., M. F. Landoni, and P. Lees. 2003. Pharmacokinetics (PK), Pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids. Antimicrob. Agents Chemother. 47:626-635.
3. Aliabadi, F., and P. Lees. 2001. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. Am. J. Vet. Res. 62:1979-1989.
4. Atkinson, H., and E. Begg. 1990. Prediction of drug distribution into human milk from physicochemical characteristics. Clin. Pharmacokinet. 18:151-167.
5. Boothe, D. M. 1994. Enrofloxacin revisited. Vet. Med. (Praha) 89:744-753.
6. Brown, S. A. 1996. Fluoroquinolones in animal health. J. Vet. Pharmacol. Ther. 19:1-14.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
8. Davis, J. L., M. G. Papich, and A. Weingarten. 2006. The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J. Vet. Pharmacol. Ther. 29:191-197.
9. Fang, W., and S. Pyörälä. 1996. Mastitis-causing Escherichia coli: Serum sensitivity and susceptibility to selected antibacterials in milk. J. Dairy Sci. 79:76-82.
10. Fernández-Varón, E., I. Ayala, P. Marín, A. Carrión, N. Martos, E. Escudero, and C. M. Cárceles. 2006a. Pharmacokinetics of danofloxacin in horses after intravenous, intramuscular and intragastric administration. Equine Vet. J. 38:342-346.
11. Fernández-Varón, E., L. Villamayor, E. Escudero, A. Espuny, and C. M. Cárceles. 2006b. Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Vet. J. 172:302-307.
12. Gehring, R., and G. W. Smith. 2006. An overview of factors affecting the disposition of intramammary preparations used to treat bovine mastitis. J. Vet. Pharmacol. Ther. 29:237-241.
13. Gibaldi, M., and P. Perrier. 1982. Pharmacokinetics. Marcel Dekker Inc., New York, NY.
14. Giles, C. J., R. A. Magonigle, W. T. R. Grimshaw, A. C. Tanner, J. E. Risk, M. J. Lynch, and J. R. Rice. 1991. Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. Vet. Pharmacol. Ther. 14:400-410.
15. Gutiérrez, C. B., and E. F. Rodríguez. 1993. In vitro susceptibility of Pasteurella multocida subspecies multocida strains isolated from swine to 42 antimicrobial agents. Zentralbl. Bakteriol. 270:387-393.
16. Haines, G. R., M. P. Brown, R. R. Gronwall, K. A. Merritt, and L. K. Baltzley. 2001. Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can. J. Vet. Res. 65:181-187.
17. Hannan, P. C. T., G. D. Windsor, A. Jong, N. Schmeer, and M. Stegemann. 1997. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob. Agents Chemother. 41:2037-2040.
18. Heinen, E. 2002. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin and orbifloxacin in dogs after single oral administration. J. Vet. Pharmacol. Ther. 25:1-5.
19. Lode, H., K. Borner, and P. Koeppe. 1998. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27:33-39.
20. Marín, P., C. M. Cárceles, E. Escudero, and E. Fernández-Varón. 2007a. Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. Can. J. Vet. Res. 71:74-76.
21. Marín, P., E. Escudero, E. Fernández-Varón, and C. M. Cárceles. 2007b. Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. J. Vet. Pharmacol. Ther. 30:74-79.
22. McManaman, J. L., and M. C. Neville. 2003. Mammary physiology and milk secretion. Adv. Drug Deliv. Rev. 55:629-641.
23. Nakamura, S. 1995. Veterinary use of the new quinolones in Japan. Drugs 49(Suppl. 2):152-158.
24. Nightingale, C. H., E. M. Grant, and R. Quintiliani. 2000. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 46:6-14.
25. Powers, J. 1990. Statistical analysis of pharmacokinetics data. J. Vet. Pharmacol. Ther. 13:113-120.
26. Shem-Tov, M., G. Ziv, A. Glickman, and A. Saran. 1997. Pharmacokinetics and penetration of danofloxacin from the blood into the milk of ewes. Vet. Res. 28:571-579.
27. Shumaker, R. C. 1986. PKCALC: A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev. 17:331-348.
28. Siefert, H. M., C. Kohlsdorfer, W. Steinke, and A. Witt. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: Tissue distribution in male rats. J. Antimicrob. Chemother. 43(Suppl. B):61-67.
29. Toutain, P. L., and P. Lees. 2004. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimise dosage regimens in veterinary medicine. J. Vet. Pharmacol. Ther. 27:467-477.
30. Turnidge, J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58:29-36.
31. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antibacterial pharmacokinetic parameters with therapeutic efficacy in animal models. J. Infect. Dis. 158:831-847.
32. Watts, J. L., S. A. Salmon, M. S. Sanchez, and R. J. Yancey. 1997. In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance. Antimicrob. Agents Chemother. 41:1190-1192.
33. Waxman, S., C. Rodríguez, F. González, M. L. De Vicente, M. I. San Andrés, and M. D. San Andrés. 2001. Pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in adult goats. J. Vet. Pharmacol. Ther. 24:375-378.
34. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.
35. Yamaoka, K., Y. Tamigawara, and J. Uno. 1981. A pharmacokinetic analysis program (MULTI) for microcomputers. J. Pharmacobiodyn. 4:879-885.
36. Ziv, G. 1980. Drug selection and use in mastitis: Systemic vs. local therapy. J. Am. Vet. Med. Assoc. 176:1109-1115.